News release

Date: 08/09/2023
Voluntary Recall of three ( 3 ) lots of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP).

Apotex has initiated a voluntary Type I recall to the Pharmacy Level for three lots (PY1833, RM0518 and PV0569) of “APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)”. This is due to three ( 3 ) lots in which the interim acceptable concentration limit of 2.5 ppm for N-Nitrosonortriptyline (NNORT), as established by Health Canada, has been exceeded. To date, there are no relevant adverse event reports or complaints received for any of these three ( 3 ) lots. The details for the lots being recalled are listed below:

APO-AMITRIPTYLINE (Amitriptyline hydrochloride) is indicated in the treatment and management of depressive illness of psychotic or endogenous nature and in selected patients with neurotic depression, and is also of value in alleviating the anxiety component of depression. As with other tricyclic antidepressants, APO-AMITRIPTYLINE may precipitate hypomanic episodes in patients with bipolar depression. These drugs are not indicated in mild depressive states and depressive reactions.

To report a suspected adverse reaction associated with the use of APO-AMITRIPTYLINE (Amitriptyline hydrochloride Tablets USP) patients may contact Apotex by calling 1-800-667-4708 or 416-401-7780 (follow prompts), by email at [email protected] or by fax at 1-866-429-9133 or 416-401-3819.

Patients may also report any suspected adverse reactions associated with the use of health products to Health Canada by calling toll free at 1-866-234-2345 or by visiting MedEffect Canada's Web page on Adverse Reaction Reporting https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html for information on how to report online, by mail or by fax.